|

LET Optimized IMPT in Treating Pediatric Patients With Ependymoma

RECRUITINGPhase 1Sponsored by M.D. Anderson Cancer Center
Actively Recruiting
PhasePhase 1
SponsorM.D. Anderson Cancer Center
Started2019-04-01
Est. completion2027-12-31
Eligibility
Healthy vol.Accepted
Locations2 sites
View on ClinicalTrials.gov →

NCT03750513

Summary

This phase I trial studies the side effects of linear energy transfer (LET) optimized image modulated proton therapy (IMPT) in treating pediatric patients with ependymoma. Radiation therapy such as LET optimized IMPT, uses proton beams to kill tumor cells and shrink tumors without damaging surrounding normal tissues.

Eligibility

Healthy volunteers accepted
Inclusion Criteria:

* Previous pathologic confirmation of ependymoma, World Health Organization (WHO) grade II or III
* Disease must be confined to the brain (no evidence of spread on MR imaging of the spine or on staging lumbar puncture)
* Patient may not receive chemotherapy concurrent with radiation
* Signed informed consent by patient and/or parents or legal guardian
* Lansky performance status score of 50 -100

Exclusion Criteria:

* Patients with previous radiation therapy to the brain
* Ependymoma of the spine
* Disseminated ependymoma requiring craniospinal radiation therapy
* Pregnancy
* Inability to undergo MR imaging
* Inability to receive gadolinium-based contrast agent

Conditions3

Anaplastic EpendymomaCancerEpendymoma

Locations2 sites

Massachusetts

1 site
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114
Kaden L Mitra Litzingerklitzinger@mgh.harvard.edu

Texas

1 site
M D Anderson Cancer Center
Houston, Texas, 77030
David R. Grosshans713-563-2300

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.